Original Article

Wavefront-guided Photorefractive Keratectomy With the VISX Platform for Myopia

Simon R. Bababeygy, MD; Edward E. Manche, MD

Journal of Refractive Surgery
March 2011 - Volume 27 · Issue 3: 173-180

DOI: 10.3928/1081597X-20100527-01

PURPOSE

To evaluate the safety, efficacy, and clinical outcome of wavefront-guided photorefractive keratectomy (PRK) for the treatment of low to moderate and high myopia and compound myopic astigmatism.

METHODS

This retrospective study included 174 eyes of 102 patients with low to moderate (–0.125 to <–6.50 diopters [D]) and high (>–6.50 D) myopia treated with wavefront-guided PRK using the VISX CustomVue S4 IR (Abbott Medical Optics) excimer laser. Eyes were analyzed preoperatively and at 1, 3, 6, and 12 months postoperatively. At 3 months, 174 eyes of 102 patients were evaluated, and at 12 months, 146 eyes of 75 patients were evaluated. No eyes were retreated in the study.

RESULTS

Mean patient age was 38.3±8.76 years (range: 20 to 66 years), and mean preoperative manifest refraction spherical equivalent (MRSE) was –5.60±2.58 D (range: –0.13 to –10.50 D). At 12 months postoperative, MRSE was –0.16±0.45 D (range: –1.50 to 1.38 D); 96.6% of eyes were within ±1.00 D of intended correction, whereas 81.5% were within ±0.50 D of intended correction. For all eyes, the safety and efficacy indexes were 1.01 and 1.02, respectively.

CONCLUSIONS

These data support the safety and efficacy for the correction of low to moderate and high myopia and compound myopic astigmatism using wavefront-guided PRK. [J Refract Surg. 2011;27(3):173-180.]

doi:10.3928/1081597X-20100527-01

AUTHORS

From the Department of Ophthalmology (Bababeygy, Manche) and Howard Hughes Medical Institute (Bababeygy), Stanford University School of Medicine, Stanford; and Doheny Eye Institute and the Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles (Bababeygy), California.

The authors have no proprietary or financial interest in the materials presented herein.

Correspondence: Edward E. Manche, MD, Stanford University School of Medicine, Dept of Ophthalmology, 900 Blake Wilbur Dr, Room W3002, Stanford, CA 94305. Tel: 650.723.6661; Fax: 650.723.6619; E-mail: Edward.Manche@stanford.edu

Received: December 4, 2009; Accepted: April 30, 2010

Posted online: June 15, 2010

Comments

There are no comments for this article. Be the first to comment.

Your comment
Name:
Email:
Comments:

Comments are reviewed for suitability prior to posting